The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses: Developed and approved at the national cancer institute workshop in Bethesda, MD, December 12–13, 1988

@article{Soloman1989The1B,
  title={The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses: Developed and approved at the national cancer institute workshop in Bethesda, MD, December 12–13, 1988},
  author={Diana Elena Soloman},
  journal={Diagnostic Cytopathology},
  year={1989},
  volume={5}
}
  • D. Soloman
  • Published 1 July 1989
  • Medicine
  • Diagnostic Cytopathology
The Bethesda System for reporting cervical/vaginal diagnoses, introduced in this article, is a flexible guideline and can be modified as appropriate to meet the needs of cytopathologists, referring physicians, and patients. 

Topics from this paper

The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology
TLDR
The Yokohama System (TYS) Working Group, composed of cytopathologists, surgical pathologists, and gynecologic oncologists, met at the 2016 International Congress of Cytology, Yokohamas, with the aim to publish a standardized reporting system inclusive of specific diagnostic categories and cytomorphologic criteria for uniform and reliable diagnosis of endometrial malignancies.
Review of the Bethesda System atlas does not improve reproducibility or accuracy in the classification of atypical squamous cells of undetermined significance smears
TLDR
The authors assessed whether group study of TBS atlas improves the reproducibility and accuracy of the cytopathologic diagnosis of equivocal Papanicolaou smears.
The Pap Test and Bethesda 2014
TLDR
The process and rationale by which updates were made to the terminology in 2014 are summarized and the contents of the new, third edition of the Bethesda atlas and corresponding website are outlined.
Should adequacy criteria in cervicovaginal cytology be modified after radiotherapy, chemotherapy, or hysterectomy?
TLDR
The general criterion of an unsatisfactory Papanicolaou (Pap) test in the 2001 version of the Bethesda system is not applicable to patients after treatment with radiotherapy, chemotherapy, or hysterectomy, so specimen adequacy criteria for Pap tests should be modified for these conditions.
Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test
TLDR
The category of Atypical Squamous Cells of Undetermined Significance (ASCUS)‐favor reactive has been eliminated and a recommendation for cytologists to judiciously downgrade those Papanicolaou (Pap) tests that would formerly have been in this category to Negative for Intraepithelial Lesion or Malignancy (NILM).
Papanicolaou Society of Cytopathology guidelines for educational notes, disclaimers, and similar comments on reports of cervical cytology specimens
TLDR
A list of suggested guidelines to aid practicing cytopathologists in conforming to the National Cancer Institute Bethesda Workshop's consensus recommendations and to fill the requirements of the College of American Pathologists inspections are formulated.
The current status of the Papanicolaou smear
TLDR
Important issues related to the Pap smear, including cytologic nomenclature, accuracy, regulatory procedures, and screening guidelines, are still being evaluated and debated.
Papanicolaou smear history in women with low‐grade cytology before cervical cancer diagnosis
TLDR
Examination of screening histories of women diagnosed with invasive cervical cancer in 2000 who had previous Papanicolaou (Pap) smears deemed to be unsatisfactory or with low‐grade findings that did not lead to biopsy found no evidence of cancer.
Cervical Screening: History, Current Algorithms, and Future Directions
This chapter describes the principles and evaluation of cancer screening programs, the evolution and history of cytology-based cervical cancer screening programs in the UK, past and contemporary
The Pap test and Bethesda 2014
TLDR
The history of “The Bethesda System” for reporting cervical cytology goes back almost 3 decades, and 3 fundamental principles emerged that have guided TBS to this day: clear-cut thresholds for management and decrease interobserver variability.
...
1
2
3
4
5
...